JP2021502334A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502334A5 JP2021502334A5 JP2020523776A JP2020523776A JP2021502334A5 JP 2021502334 A5 JP2021502334 A5 JP 2021502334A5 JP 2020523776 A JP2020523776 A JP 2020523776A JP 2020523776 A JP2020523776 A JP 2020523776A JP 2021502334 A5 JP2021502334 A5 JP 2021502334A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- treatment
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581671P | 2017-11-04 | 2017-11-04 | |
| US62/581,671 | 2017-11-04 | ||
| US201862618916P | 2018-01-18 | 2018-01-18 | |
| US62/618,916 | 2018-01-18 | ||
| US201862681944P | 2018-06-07 | 2018-06-07 | |
| US62/681,944 | 2018-06-07 | ||
| PCT/US2018/059218 WO2019090227A1 (en) | 2017-11-04 | 2018-11-05 | Methods of treating metastatic cancers using axl decoy receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502334A JP2021502334A (ja) | 2021-01-28 |
| JP2021502334A5 true JP2021502334A5 (https=) | 2021-12-16 |
| JP7286179B2 JP7286179B2 (ja) | 2023-06-05 |
Family
ID=66333375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523776A Active JP7286179B2 (ja) | 2017-11-04 | 2018-11-05 | Ａｘｌデコイ受容体を用いる転移性癌の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200289613A1 (https=) |
| EP (1) | EP3703731A4 (https=) |
| JP (1) | JP7286179B2 (https=) |
| KR (1) | KR20200085307A (https=) |
| CN (1) | CN111565742B (https=) |
| AU (2) | AU2018359863A1 (https=) |
| CA (1) | CA3080732A1 (https=) |
| MX (1) | MX2020007130A (https=) |
| WO (1) | WO2019090227A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4062914A4 (en) | 2019-11-18 | 2024-01-17 | Inxmed (Nanjing) Co., Ltd. | USE OF AN FAK INHIBITOR IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF TUMORS PRESENTING AN NRAS MUTATION |
| WO2021141892A1 (en) * | 2020-01-06 | 2021-07-15 | Aravive Inc. | Methods of treating clear cell renal carcinoma (ccrcc) using axl decoy receptors |
| EP4101453A4 (en) | 2020-02-05 | 2024-05-15 | Inxmed (Nanjing) Co., Ltd. | COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS |
| GB202004189D0 (en) * | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| MX2023000810A (es) * | 2020-07-19 | 2023-05-19 | Aravive Inc | Metodos de diagnostico para el cancer utilizando receptores señuelo axl. |
| TW202313044A (zh) * | 2021-08-16 | 2023-04-01 | 大陸商應世生物科技（南京）有限公司 | Ｉｎ１００１８與ｐｌｄ的聯用 |
| EP4398937A4 (en) * | 2021-09-11 | 2025-07-09 | Aravive Inc | METHODS FOR TREATING LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA USING AXL DECOY RECEPTORS AS FIRST-LINE THERAPY |
| CN120418281A (zh) * | 2022-12-29 | 2025-08-01 | 财团法人生物技术开发中心 | 靶向PD-L1和中和Gas6之融合蛋白及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
| DK2352763T4 (da) | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
| PL2387395T3 (pl) * | 2009-01-16 | 2015-03-31 | Rigel Pharmaceuticals Inc | Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym |
| PT2525824T (pt) | 2010-01-22 | 2017-07-13 | Univ Leland Stanford Junior | Inibição da sinalização de axl em terapêutica antimetastática |
| US9074192B2 (en) * | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2894539C (en) * | 2012-12-14 | 2021-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US10876176B2 (en) * | 2014-12-18 | 2020-12-29 | Aravive Biologics, Inc. | Antifibrotic activity of GAS6 inhibitor |
| JP7042739B2 (ja) * | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| US20180140679A1 (en) | 2016-11-23 | 2018-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of axl receptor activity in combination with cytoreductive therapy |
-
2018
- 2018-11-05 EP EP18872866.1A patent/EP3703731A4/en active Pending
- 2018-11-05 CA CA3080732A patent/CA3080732A1/en active Pending
- 2018-11-05 MX MX2020007130A patent/MX2020007130A/es unknown
- 2018-11-05 AU AU2018359863A patent/AU2018359863A1/en not_active Abandoned
- 2018-11-05 KR KR1020207016082A patent/KR20200085307A/ko not_active Ceased
- 2018-11-05 WO PCT/US2018/059218 patent/WO2019090227A1/en not_active Ceased
- 2018-11-05 JP JP2020523776A patent/JP7286179B2/ja active Active
- 2018-11-05 CN CN201880084046.2A patent/CN111565742B/zh active Active
- 2018-11-05 US US16/761,246 patent/US20200289613A1/en not_active Abandoned
-
2023
- 2023-08-01 US US18/228,879 patent/US20240009271A1/en not_active Abandoned
-
2025
- 2025-03-06 AU AU2025201654A patent/AU2025201654A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502334A5 (https=) | ||
| Punekar et al. | Immunotherapy in non-small cell lung cancer: Past, present, and future directions | |
| Miyauchi et al. | Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics | |
| Townsend et al. | The expansion of targetable biomarkers for CAR T cell therapy | |
| ES2951650T3 (es) | Uso de un anticuerpo anti-PD-1 junto con un anticuerpo anti-CD30 en el tratamiento del linfoma | |
| CN114423446A (zh) | 用于癌症免疫治疗的组合物和方法 | |
| Vacchelli et al. | Trial watch: immunostimulatory cytokines in cancer therapy | |
| Zarrabi et al. | Emerging therapeutic agents for genitourinary cancers | |
| CN110996952A (zh) | 用于治疗癌症的方法 | |
| RU2014111999A (ru) | Антитела к C10RF32 и их применения для лечения рака | |
| CN111565742B (zh) | 使用axl诱骗受体治疗转移性癌症的方法 | |
| Tojjari et al. | Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2 | |
| WO2018039332A1 (en) | Immunoswitch nanoparticles for reprogrammed t cell responses | |
| Jou | Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential | |
| JP2024542682A (ja) | 治療 | |
| Naing et al. | First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors | |
| JP2022541344A5 (https=) | ||
| US20240350589A1 (en) | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer | |
| US20250123284A1 (en) | Diagnostic methods for cancer using ephrinb2 expression | |
| JP2023535352A5 (https=) | ||
| JP2024534935A5 (https=) | ||
| KR20230050349A (ko) | Axl 유인 수용체를 이용한 암의 진단 방법 | |
| US20260069692A1 (en) | Modified t-cells for use in the treatment of gastroesophageal cancer | |
| US20230331849A1 (en) | CpG IMMUNOCONJUGATES FOR CANCER THERAPY | |
| RU2785866C2 (ru) | Способы лечения метастатических видов рака с использованием рецепторов-ловушек axl |